CHPG sodium salt 是一个选择性的mGluR5激动剂,并且通过TSG-6/NF-κB途径减弱 BV2 小神经胶质细胞 SO2诱导的氧化应激和炎症。 CHPG sodium salt 通过ERK和Akt途径在体外和体内预防创伤性脑损伤 (TBI)。
生物活性 | CHPG sodium salt is a selectivemGluR5agonist, and attenuates SO2-induced oxidative stress and inflammation throughTSG-6/NF-κBpathway in BV2 microglial cells[1]. CHPG sodium salt protects against traumatic brain injury (TBI) in vitro and in vivo by activation of theERKandAktsignaling pathways.[2]. |
IC50& Target | |
体外研究 (In Vitro) | CHPG sodium salt (10-500 μM; 24 hours) significantly increases the cell viability and decreases the LDH release after SO2derivatives treatment[1]. CHPG sodium salt (0.5 mM; 30 mins ) protects BV2 cells against SO2-induced apoptosis[1]. CHPG sodium salt (0.5 mM; 30 mins) treatment alone increases the expression of TSG-6 in both mRNA and protein levels[1].
Cell Viability Assay[1] Cell Line: | BV2 microglial cells | Concentration: | 10, 50, 100 and 500 μM | Incubation Time: | 24 hours | Result: | Increased the cell viability. |
Apoptosis Analysis[1] Cell Line: | BV2 microglial cells | Concentration: | 0.5 mM | Incubation Time: | 30 mins | Result: | Protected BV2 cells against SO2-induced apoptosis. |
Western Blot Analysis[1] Cell Line: | BV2 microglial cells | Concentration: | 0.5 mM | Incubation Time: | 30 mins | Result: | Increased the expression of TSG-6 in both mRNA and protein levels. |
|
体内研究 (In Vivo) | CHPG sodium salt (injection; 250 nM; for 7 days) reduces significantly cerebral lesion volume[2].
Animal Model: | Adult Sprague-Dawley male rats weighing 280-320 g[2] | Dosage: | 250 nM | Administration: | Injection; for 7 days | Result: | Reduced significantly cerebral lesion volume. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: DMSO : 100 mg/mL(447.25 mM;Need ultrasonic) H2O : 6.67 mg/mL(29.83 mM;ultrasonic and warming and heat to 80℃) 配制储备液 1 mM | 4.4725 mL | 22.3624 mL | 44.7247 mL | 5 mM | 0.8945 mL | 4.4725 mL | 8.9449 mL | 10 mM | 0.4472 mL | 2.2362 mL | 4.4725 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: PBS Solubility: 5 mg/mL (22.36 mM); Clear solution; Need ultrasonic and warming and heat to 60℃ 2. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (11.18 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (11.18 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (11.18 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (11.18 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 4. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (11.18 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (11.18 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|